Chemicals

Why 2021 will be a pivotal year for life sciences patents in China

Despite radical reforms, pharma and biotech innovators still have unanswered questions about the country’s IP system

Why 2021 will be a pivotal year for life sciences patents in China
Six life sciences IP dealmaking trends to watch out for in 2021
19 Jan 2021

Six life sciences IP dealmaking trends to watch out for in 2021

Despite a turbulent 2020 for pharma transactions, it is possible to discern a few patterns for activity in the market this year

New Brazilian biotech patent examination guidelines a “missed opportunity”
14 Jan 2021

New Brazilian biotech patent examination guidelines a “missed opportunity”

While boosting transparency, the many difficulties faced by life sciences innovators when applying for protection in the country are not addressed

Latest

View all
22 Dec 2020

Three life sciences trade secrets and data strategy lessons

As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies. Read more

18 Dec 2020

Patent data shows the complexity of the semiconductor manufacturing market

There is no clear stand-out in what is a highly interconnected industry. Instead a host of companies all rank as innovation leaders Read more

17 Dec 2020

What you need to know about post-Brexit changes to the UK’s SPC system

Failures to update IP management following the New Year could be costly for life sciences businesses Read more

16 Dec 2020

Five key insights into 2020’s drug royalty transactions

It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver Read more

News

View all
15 Dec 2020

East Asian giants leave their stamp on the IP market

IAM reveals the Asia IP Elite members for 2020 from two dynamic high-tech jurisdictions: South Korea and Taiwan Read more

14 Dec 2020

The Asia IP Elite – a shared commitment to excellence across very different markets

IAM reveals the top in-house IP teams from India, Southeast Asia and Australasia Read more

19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

14 Sep 2020

Changes to Ukraine’s IP laws have major implications for the life sciences

Two recent pieces of legislation have brought the country’s patent system more closely in line with EU rules Read more

Analysis

View all
10 Dec 2020

Korea’s tough selection patent inventiveness rules may be overturned

The country’s Supreme Court is expected to hand down a potentially momentous decision in the coming months Read more

10 Dec 2020

China’s gene sequencing equipment champion seeks public listing amidst sprawling global patent battle

BGI and its sequencer-manufacturing subsidiary MGI Tech made over 70% of their revenue abroad last year, but face over 20 patent assertions in overseas markets Read more

8 Dec 2020

Australian vaccine patent ruling shows tough new support requirements for life sciences innovators

Wyeth’s dispute with MSD underscores move towards stricter, UK-style disclosure obligations for IP rights Read more

3 Dec 2020

New patent politics put US public-private partnerships under threat, says BIO’s IP chief

In an exclusive interview, Hans Sauer talks of concerns over a shift in federal strategy and argues that government research funding should not be seen as a commercial investment Read more

Insights

View all
12 Aug 2020

IP market news highlights

A rundown of some of the top news stories on the IAM platform in May, June and July Read more

12 Aug 2020

As the fallout from covid continues, the two IP superpowers offer different messages

While China cheers an uptick in applications, the USPTO warns of a prolonged downturn Read more

8 Jun 2020

From French fancy to global community – celebrating 100 issues of IAM 

Founder and editor in chief Joff Wild looks back on 17 years of IAM Read more